Broader MedTech industry at turning point, seeking positioning to optimize portfolios, differentiate technology and improve R&D

- Innovation drives increased dealmaking and R&D investment: MedTech saw a resurgence in deal size with M&A value up 160% in the first half of 2026 vs. the same period in 2025, reflecting investments in next-generation technologies, including AI-enabled diagnostics, robotics, structural heart, diabetes care and minimally invasive therapies.

- AI is reshaping the future of value creation: AI integration in MedTech is unlocking new business opportunities and scalable value creation, alongside a record and growing number of FDA-authorized AI-enabled devices.

- Industry growth is expanding into alternative care settings: MedTech is increasingly moving beyond traditional care settings and capturing growth in alternative care markets, particularly the rapidly expanding ambulatory surgery center (ASC) market and direct to consumer/patient.

NEW YORK, Oct. 19, 2026 /PRNewswire/ -- The 20th edition of the Ernst & Young LLP (EY US) Pulse of the MedTech Industry report finds that the global medical technology (MedTech) industry is at a turning point. Following a period of record-setting growth and investment across the US and Europe, the sector finds itself at a revenue high point, even amid challenges, including negative investor sentiment and persistent global trade and supply chain uncertainties.

Despite a challenging operating environment, the MedTech industry saw sustained growth in 2025, reaching approximately US$650 billion in revenue and representing growth of 11%, and continued to demonstrate top-line performance in the first half of 2026, generating $325 billion in revenue, a 7.1% increase compared with the same time period in 2025. Therapeutic devices led industry growth, followed by non-imaging diagnostic, imaging, and lab equipment and tools. However, growth was highly concentrated among commercial leaders, highlighting a widening performance gap across the industry.

"MedTech has rebounded from YTD June lows and has underperformed the broader markets in 2026. The sector has continued to demonstrate resiliency, with record revenue financing and strong M&A activity setting the stage for a bright future," says John Babitt, EY Global MedTech Leader. "The broader sector players are at a turning point where discipline is essential to convert innovation into profitable growth."

Other key findings include:

- MedTech financing reached a record US$63 billion for the year ended June 30, 2026, up 87% year over year – the highest seen in the last decade. Together, initial public offerings and debt accounted for around 80% of total capital raised, indicating that recovery has been driven primarily by public-market reopening and strategic balance sheet financing rather than broad-based funding strength.

- MedTech M&A reached its highest level in more than a decade, with total disclosed deal value surging to roughly US$130 billion. However, this recovery was driven by a limited number of blockbuster transactions.

- Innovation remains at the core of MedTech's heartbeat, with growth largely driven by a breakout group of high-performing, high-differentiation, high-innovation strategic leaders. Companies that delivered both high R&D productivity and EBIT margin expansion generated an average total shareholder return of approximately 13.8%.

- AI in MedTech is observing a transformation, with intelligence being deeply embedded into devices and the care pathways around them. Hardware design, clinical evidence and manufacturing quality will remain fundamental and are increasingly being complemented by the quality of the algorithms, data and digital services surrounding the product.

- Venture capital fundraising remained resilient in 2026, with overall activity skewed toward earlier-stage innovation, highlighting improved investment activity and continued investor conviction in differentiated technologies addressing significant unmet clinical needs.

"MedTech is entering a new era of growth, and today's challenges are the catalyst for the industry's next transformations," says Diana Hoff, EY Americas Life Sciences Sector Leader. "As companies navigate margin pressure, supply chain risk and global trade uncertainty, the leaders of the next decade will be those that embrace AI, make more deliberate portfolio choices and build productive, resilient operating models that turn innovation into sustained growth and value."

Looking ahead, MedTechs that maintain innovation while also building conviction across capital allocation and portfolio optimization will be best positioned to set the pace of the pulse of the industry in the years to come.

To read Pulse of the MedTech Industry, please visit https://www.ey.com/en_us/life-sciences/pulse-of-medtech-industry-outlook?WT.mc_id=14001805&AA.tsrc=pr.

About EY

EY is building a better working world by creating new value for clients, people, society and the planet, while building trust in capital markets.

Enabled by data, AI and advanced technology, EY teams help clients shape the future with confidence and develop answers for the most pressing issues of today and tomorrow.

EY teams work across a full spectrum of services in assurance, consulting, tax, strategy and transactions.

Fueled by sector insights, a globally connected, multidisciplinary network and diverse ecosystem partners, EY teams can provide services in more than 150 countries and territories.

All in to shape the future with confidence.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.

Ernst & Young LLP is a client-serving member firm of Ernst & Young Global Limited operating in the US.

About EY Consumer and Health

The rise of the empowered consumer, coupled with technology advancements and the emergence of digitally focused entrants, is changing every aspect of health and care delivery. To retain relevancy in today's digitally focused, data-infused ecosystem, all participants in healthcare today must rethink their business practices, including capital strategy, partnering and the creation of patient-centric operating models.

The EY Consumer and Health architecture brings together a worldwide network of 34,000 professionals to build data-centric approaches to customer engagement and improved outcomes. We help our clients deliver on their strategic goals, design optimized operating models and form the right partnerships so they may thrive today and succeed in the health systems of tomorrow. We work across the ecosystem to understand the implications of today's trends, proactively finding solutions to business issues, and to seize the upside of disruption in this transformative age.

Media contact: Carol Piering, [email protected]

SOURCE EY

Share this article

Clinical ink Announces Strategic Investment from Ardan Equity and GI Partners to Accelerate Next Phase of Growth

Ardan and GI to bring deep, complementary domain expertise across life sciences and healthcare technology and partner with management to further accelerate Clinical ink's growth

WINSTON-SALEM, N.C., Oct. 19, 2026 /PRNewswire/ -- Clinical ink, a global clinical trial technology company, today announced investments from Ardan Equity ("Ardan"), a private equity firm specializing in healthcare technology, through Ardan Equity Fund I and from GI Partners ("GI"), a leading private investment firm that has partnered with the company since 2020, through GI Partners Fund VI. Existing investors, including GI Partners Fund V, realized a full exit of their prior investments, and Ardan and GI Partners both invested new equity in a co-control partnership.

Clinical ink provides electronic clinical outcome assessments (eCOA), connected device and other eClinical technologies to pharmaceutical companies and contract research organizations (CROs) to capture complex clinical trial data. Its combination of configurable technology, complex endpoint expertise, and integrated device capabilities support the latest FDA requirements in clinical trials as well as the emerging era of technology-enabled clinical care.

Drawing on their complementary life sciences and healthcare technology expertise, Ardan and GI will collaborate closely with management to continue to scale the Clinical ink platform globally, pursue opportunities across clinical research and care, and deliver innovative solutions that meet the rapidly evolving needs of the industry, while maintaining the highest standards of quality and compliance.

Since GI's initial investment in 2020, Clinical ink has expanded its global footprint, market position, platform, and capabilities. During that time, the company has meaningfully grown revenue, expanded therapeutic areas, deepened preferred provider relationships with leading pharmaceutical companies, launched differentiated solutions (including GlucoseReady and SPUR), and began its expansion into clinical care disease management through the Kaitality™ application.

Dave Kreter, Managing Director and Head of Healthcare at GI Partners, said, "We are pleased with the performance of the company since our 2020 investment and the tremendous progress the company has made in expanding its customer base and strengthening its position as a leading global clinical trial technology provider. Our partnership with CEO Jonathan Goldman and the Clinical ink team, together with GI's decade-plus experience investing in the healthcare technology and pharma services space, have delivered strong results to date. Looking ahead, we believe the accelerating pace of pharma R&D, the increasing complexity in clinical trials, and the need for high-quality tech solutions will provide strong tailwinds behind Clinical ink, and we look forward to building on that success alongside Ardan as the company enters its next phase of growth."

"We're delighted to welcome Clinical ink as our inaugural investment in Ardan Equity Fund I and as our eighth platform investment since 2020. We believe Clinical ink is at a key inflection point, with a compelling platform, a growing portfolio of leading pharmaceutical sponsors, and a strong path towards further expanding its footprint across the industry," said Noah Lewis, Managing Partner at Ardan Equity. "Its differentiated technology, endpoint expertise, and patient-centric approach make Clinical ink a compelling partnership for Ardan and an ideal fit for our investment thesis, our healthcare and life sciences technology sector specialist strategy, and our portfolio. We look forward to partnering with GI, Jonathan Goldman and the Clinical ink management team as we seek to accelerate the company's next phase of growth."

Jonathan Goldman, MD, Chief Executive Officer of Clinical ink, stated, "The management team and I are excited to work closely with Ardan and GI Partners to drive the next chapter of Clinical ink's evolution. We were impressed with Ardan's expertise, capabilities, and commitment to our company's growth. Our team is delighted that our long-term investors at GI remain with us given their longstanding experience with the company and its growth plans. The new investment by Ardan and GI represents a very positive development for our customers, the patients they serve, and the Clinical ink team."

Centerview Partners LLC and Guggenheim Securities, LLC served as financial advisors and Ropes & Gray LLP served as legal advisor to Clinical ink and GI Partners Fund V. Goodwin Procter LLP served as legal advisor to Ardan and Kirkland & Ellis LLP served as legal advisor to GI Partners Fund VI. Raymond James also acted as financial advisor to Ardan and GI Partners Fund VI. Ernst & Young, LLP acted as financial advisor to Ardan.

About Ardan Equity

Founded in 2019, Ardan Equity is a private equity firm exclusively focused on the healthcare and life sciences technology ecosystem. Ardan partners collaboratively with founders and management teams to accelerate growth and create differentiated platforms. As founders, operators, and investors, the Ardan team has built many of the defining healthcare and life sciences technology companies across life sciences, payer, provider and employer markets. Ardan utilizes its operator-investor approach and trusted network to help drive risk-adjusted performance. The firm invests capital on behalf of leading institutional investors globally and is headquartered in Palm Beach, Florida. For more information, please visit www.ardanequity.com.

About GI Partners

Founded in 2001, GI Partners is a private investment firm with over 180 employees and offices in San Francisco, New York, Dallas, Chicago, Greenwich, Scottsdale, and London. The firm has raised more than $50 billion and invests on behalf of leading institutional investors around the world through its private equity, real estate, and data infrastructure strategies. The private equity team invests primarily in companies in the healthcare, services, and software sectors. The real estate team focuses primarily on technology and healthcare properties as well as other specialized types of real estate. The data infrastructure team invests primarily in hard asset infrastructure businesses underpinning the digital economy. For more information, please visit www.gipartners.com.

About Clinical ink

Clinical ink is a global clinical technology company that helps pharmaceutical companies capture patient and clinical data through electronic clinical outcome assessments (eCOA) and connected device solutions in complex clinical trials. Its configurable technology platform combines deep endpoint expertise with integrated device capabilities to support increasingly sophisticated studies and generate regulatory-grade data. Clinical ink is headquartered in Winston-Salem, North Carolina with offices in Iowa, Pennsylvania and Copenhagen Denmark. For more information, please visit www.clinicalink.com.

Media Contacts

Ardan Equity

Urmi Jain, Investor Relations

[email protected]

GI Partners

Chris Tofalli, Public Relations

[email protected]

Emily Kuan, Investor Relations

[email protected]

SOURCE Clinical ink

Share this article

Half of patients with the hormonal disorder, which raises risk of heart attack, stroke and kidney disease, may be undiagnosed under current screening thresholds

SECAUCUS, N.J., Oct. 19, 2026 /PRNewswire/ -- A new study finds that current medical guidelines may inadvertently lead to under-diagnosis of primary aldosteronism (PA), a hormonal disorder associated with hypertension that can significantly raise a person's risk of heart attack, stroke and kidney disease if left untreated.

Published in the journal Hypertension, a publication of the American Heart Association, the findings suggest that changing the diagnostic threshold for PA would double the detection rate, identifying thousands of high-risk patients who may otherwise be undiagnosed and untreated.

Researchers from Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, Mass General Brigham, Harvard Medical School and the University of Texas Southwestern Medical School conducted the study, based on deidentified results of lab tests performed by Quest on over 60,449 patients in the United States.

Primary aldosteronism occurs when the adrenal glands produce too much aldosterone, a hormone that helps regulate sodium and potassium in the blood. High blood pressure is a defining feature of the condition, though affected individuals may have other common symptoms like headaches or muscle cramps. If left untreated, several complications can occur.

In 2025, the Endocrine Society published guidelines that recommend screening for PA for all patients with high blood pressure and included criteria for diagnosing PA. However, the new study suggests these guidelines are "overly restrictive," with laboratory cutoffs for aldosterone levels that detect only the most advanced cases of the disease. The guideline update also recommends plasma renin activity (PRA), a blood test that measures the conversion of renin in the kidneys, as the initial screening test.

When the researchers applied the 2025 criteria (PRA ≤1 ng/mL/h, aldosterone levels ≥7.5 ng/dL, ARR > 15) to the patient cohort, only 13.0% of individuals were identified as positive for PA. However, a broader, "permissive" set of criteria (PRA ≤1 ng/mL/h, aldosterone levels >5 ng/dL, without an ARR requirement) applied to the same cohort identified approximately twice as many patients, 26.2%, with PA. Additionally, clinical conditions consistent with PA such as hypertension, hypokalemia, and atrial fibrillation (based on insurance claim billing), were enriched among patients categorized as positive for PA by the more permissive laboratory cutoffs.

Among patients identified by the more permissive criteria, a PRA score of 0.5 ng/mL/hr had 1.27 times higher odds of having hypertension compared to those with a higher (or normal) PRA (P 0.0001). Patients with a PRA of 0.25 ng/mL/hr had 2.62 times higher odds of having atrial fibrillation (P = 0.0032). 79.0% of the additional patients identified by permissive criteria were missed by the 2025 criteria because they had aldosterone levels between 5 and 7.5 ng/dL, below the ES cutoff, while approximately one in five had aldosterone levels that met the ES criteria but did not meet the ARR threshold.

The findings suggest the 2025 guidelines may guide physicians to identify only the more advanced forms of the disease and that primary aldosteronism should be viewed as a spectrum rather than a positive or negative diagnosis of disease. Earlier detection using more relaxed diagnostic criteria may help clinicians identify and intervene with care with potential to prevent long-term cardiovascular complications.

"Our findings demonstrate that current international clinical guidelines for diagnosing primary aldosteronism are optimized to identify advanced disease but may be less sensitive for earlier or milder forms of PA," said lead author Marco Marcelli, MD, a board-certified endocrinologist and Medical Director at Quest Diagnostics. "Some patients with PA spend years on a diagnostic journey before learning their hypertension, headaches and other symptoms are due to a highly treatable condition. More expansive screening and diagnostic criteria may help the medical community to quickly identify these individuals hiding in plain sight before irreversible heart damage and other adverse outcomes have occurred."

The study's strengths include its large patient cohort and its limitations include its retrospective design and lack of confirmatory testing.

Primary aldosteronism is a serious condition that affects as many as 5-10% of adults with high blood pressure. Up to 25-30% of patients with hypertension may be diagnosed with PA if the criteria identified by the Quest group will eventually be confirmed in prospective studies. High blood pressure is widely prevalent in the U.S., affecting nearly half of all adults (almost 120 million individuals). For many years, PA was considered uncommon; however, a 2024 study published in Hypertension by researchers at Quest Diagnostics shows PA is likely under-detected.

About Quest Diagnostics

Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, we help reveal new avenues to identify and treat disease, empower healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three American adults each year, and our nearly 60,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com

SOURCE Quest Diagnostics

Share this article

LAS VEGAS, Oct. 19, 2026 /PRNewswire/ -- NICHOLAS AIR will return to the 2026 National Business Aviation Association Business Aviation Convention & Exhibition (NBAA-BACE) in Las Vegas, Nevada from October 19-22. The conference serves as the largest annual gathering for the business aviation community and brings together industry pioneers, flight department leadership, and operational experts from across the globe.

A centerpiece of the company's presence at this year's convention will be an exclusive fireside chat featuring NICHOLAS AIR Founder and Chief Executive Officer, Nicholas Correnti. The session is scheduled for Tuesday, October 20th at 2:15 PM on the Horizon Stage.

During the discussion, Correnti will provide strategic insight into the evolving operational challenges in private aviation. Key topics will address navigating OEM part supply disruptions, Engine OEM program shortfalls, and working through antiquated regulatory bottlenecks.

"NBAA-BACE continues to be a key event for innovation and leadership in our industry and provides a vital forum to address the operational challenges that operators face today," said Nicholas Correnti, Founder and CEO of NICHOLAS AIR. "From maintaining fleet reliability amid OEM shortfalls to navigating regulatory barriers, our priority continues to be executing at the highest standard for our Members. We look forward to engaging with our peers and sharing our approach to help our industry evolve."

Throughout the convention, attendees, prospective flight operations personnel, and corporate partners are invited to connect with NICHOLAS AIR representatives to discuss operational innovations, pilot career pathways, and the company's dedicated approach to safety and aircraft management.

About NICHOLAS AIR

NICHOLAS AIR is the Standard of private aviation in the United States, distinguished by owning and operating the industry's most exclusive fleet for its national Members. For nearly 30 years, the company has remained true to an authentic heritage built on uncompromising quality, consistency, and trust—delivering an elevated private travel experience for its Private Jet Card Members and Fractional Owners. Every day, every flight, NICHOLAS AIR continues to define the premium standard of Part 135 operators.

Media Contact:

Paxton Song

[email protected]

www.nicholasair.com

SOURCE Nicholas Air

Share this article

Breaking the Limits, Generation After Generation: The HONOR X Series Durability Legacy

From reinforced glass to two Guinness World Records — how every HONOR X Series phone broke the limit of its class, and how HONOR X9e Pro breaks nearly all of them at once.

DUBAI, UAE, Oct. 19, 2026 /PRNewswire/ -- Durability has become one of the most recognisable signatures of HONOR's X Series. But that reputation wasn't built by one tough phone, it was built by a pattern. Generation after generation, HONOR hasn't just made the X Series tougher. It has made each new model the phone that broke the limit of what a device in its class was expected to survive: independently certified, put through record-breaking public tests, and, twice now, enshrined in the Guinness Book of World Records. Generation after generation, the X Series has become known for pushing beyond what a smartphone in its class is expected to withstand, earning its reputation as a truly unbreakable series.

From reinforced displays to whole-device protection, from drop resistance to water, dust and battery endurance, the X Series story is one of continuously raising — and breaking — the benchmark. With HONOR X9e Pro, that legacy reaches its most advanced chapter yet: a phone that doesn't break one limit at a time, but several of them at once.

X9a: Breaking the Limit on What a Display Could Survive

The story starts with the display, because that's traditionally where phones fail first.

HONOR X9a introduced deeply reinforced 0.65mm glass capable of withstanding more than 900MPa of stress — at a time when most phones in its class treated the screen as the weak point rather than an engineered one. HONOR tested the device through marble drops, squeezing, rolling and steel-ball impact, establishing early on that resistance to everyday damage would become the defining trait of the X Series. HONOR X9a was known the smartphone with the strongest display at that time.

X9b: The First Phone in the Industry to Prove It

HONOR X9b turned that philosophy into a much stronger, and independently verified, proposition. Its HONOR Ultra-Bounce Anti-Drop technology delivered 360-degree whole-device protection, reinforcing not just the screen but the frame and internal compartments, and supported drop resistance from heights of up to 1.5 metres.

Crucially, this generation is where the claims stopped being HONOR's alone. X9b became the first smartphone in the entire industry to receive Switzerland's SGS Five-Star Overall Drop Resistance Certification, the moment durability shifted from something HONOR claimed to something that could be externally tested, scored and verified.

X9c: Breaking the Limit on Paper Then in Front of 264 People

X9c raised the benchmark again, expanding protection to cover drop, water and scratch resistance, with certified drop resistance climbing to 2 metres. It became the world's first smartphone to achieve SGS's Five-Star Comprehensive Reliability Certification — a shift from protecting individual components to certifying the reliability of the whole device.

Then HONOR took that confidence out of the lab. On 6 January 2025, 264 people simultaneously dropped HONOR X9c smartphones screen-first from shoulder height during a launch event in Manila, Philippines. Every single device counted in the attempt survived, earning HONOR Philippines an official Guinness World Records title for the Most People Performing a Mobile Phone Drop Test Simultaneously, the first time the X Series legacy was written into the record books.

X9d: Breaking the Height Limit Altogether

X9d pushed the ambition further still, adding a six-layer drop-resistant structure, tougher water and dust protection up to IP69K with 30 minutes of submersion at 1.5 metres, and a substantially larger battery to back up its "Unbreakable AI Smartphone" positioning. It became the first phone to hold both the SGS Triple-Resistant Premium Performance Certification and the SGS 5-Star Comprehensive Reliability Certification at the same time.

And then it went after the biggest record yet. In September 2025, HONOR X9d survived an intact free fall from 6.133 metres under controlled testing conditions — more than four times the drop height X9b had been certified for just two generations earlier — earning a second Guinness World Records title for the Highest Drop of a Smartphone.

HONOR X9e Pro: Where the Legacy Breaks Every Limit at Once

Every generation before it broke one limit at a time — a height, a certification, a record. HONOR X9e Pro is where that pattern changes: durability is now engineered as one connected system, and it pushes past the previous limit on nearly every axis simultaneously, rather than picking a single headline number to chase.

Arch-shaped impact-dispersal structures around the corners and perimeter, supported by high-strength metal reinforcement in the mid-frame, redirect the force of a fall away from the display and mainboard — supporting drops from up to 3 metres onto smooth marble and earning SGS Five-Star certification for Drop Resistance in Harsh Scenarios. A continuous PUR shear-resistant adhesive around the display edges delivers approximately 10 times the shear resistance[1] of a conventional backing adhesive, reducing movement between display and frame on impact.

On the water and dust side, X9e Pro carries IP68, IP69 and IP69K ratings together, tested through immersion at depths of up to 10 metres, roughly 100,000 water-exposure cycles and a 24-hour continuous salt-spray test. It's also rated to withstand hot-water exposure up to 85°C[2], an industry-leading heat-resistance claim in its class.

And the battery breaks its own limit too: an 11,000mAh fourth-generation silicon-carbon battery — 2,700mAh larger than the previous generation and the largest in its category — while the phone stays approximately 8.08mm thin and around 203g. Toughness, this time, doesn't come at the cost of the everyday smartphone experience.

A Legacy Defined by Breaking the Bar, Not Just Raising It

Each X Series generation didn't just replace the last one. It had to prove, independently and often publicly, that it had broken the limit the previous phone set. That is the legacy HONOR X9e Pro inherits — and, on nearly every front, the one it now extends.

[1] Data comes from HONOR labs.

[2] Data comes from HONOR labs.

SOURCE HONOR

Share this article

New campaign connects AI-powered performance insights linking advanced molecular intelligence to help detect cancer in earlier stages

IRVING, Texas, Oct. 19, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced the launch of the second commercial in a series promoting Caris Detect™, Caris' multi-cancer early detection (MCED) test, featuring three-time major champion professional golfer, Jordan Spieth.

The campaign emphasizes that while modern technology can measure nearly every aspect of athletic performance, the same level of intelligence can be applied to helping people find early stage cancer – when treatment is most effective. The new commercial explores how artificial intelligence has transformed golf, analyzing millions of swings and countless data points to help players improve performance. The commercial highlights how Caris is applying decades of expertise in molecular science and artificial intelligence to help identify cancer-associated molecular signals through a simple blood draw.

"Artificial intelligence is transforming nearly every aspect of our lives, from how we work and communicate to how athletes refine their performance," said David Dean Halbert, Founder, Chairman and Chief Executive Officer of Caris Life Sciences. "At Caris, we believe one of the most important applications of AI is helping advance early stage cancer detection. Caris Detect combines comprehensive molecular analysis with advanced artificial intelligence to help create a future where cancer may be detected in early stage, when there is the best chance for cure."

"Every golfer is looking for an edge. We use technology to measure everything from ball speed to spin rate because better information leads to better decisions. That's what resonated with me about Caris Detect. If advanced artificial intelligence can help us understand our golf game, it should also help us better understand our health. Raising awareness about the importance of early detection is something I'm proud to support," said Jordan Spieth, three-time major champion professional golfer.

Unlike approaches that evaluate only a limited subset of biomarkers, Caris Detect™ leverages ultra-deep leverages Whole Genome Sequencing (WGS) for all 23,000 genes, Whole Transcriptome Sequencing (WTS) and advanced artificial intelligence to analyze the full breadth of cancer-associated molecular signals in both DNA and RNA. This comprehensive approach is designed to provide a more complete picture of early stage cancer biology, enabling the identification of molecular patterns associated with cancer through a single blood draw and helping support earlier stage detection when cancers are most treatable.

Individuals interested in learning more about Caris Detect may visit CarisDetect.com.

About Caris Detect

Caris Detect™ is a multi-cancer early detection blood test designed to identify cancer-associated molecular signals using ultra-deep Whole Genome Sequencing, Whole Transcriptome Sequencing and advanced artificial intelligence. The test analyzes a broad range of molecular information to help detect cancer-associated signals at the earliest stage of disease, when it is most curable.

About Caris Life Sciences 

Caris Life Sciences® (Caris) is a leading TechBio company actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.  

Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.  

Forward Looking Statements

This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," or "continue" or similar expressions.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: continued development, performance and commercialization of Caris Detect; developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; the impact on our future volumes of the continued execution of our strategy to re-align and expand our sales organization; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions, including our application for New York State Department of Health approval for Caris Assure; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties; and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.

Caris Life Sciences Media:  

Corporate Communications

[email protected]

214.294.5606 

SOURCE Caris Life Sciences

Share this article

KAILAS Becomes Title Sponsor of the FWT China Series, Opening a New Freeride Season Through BEYOND THE GATE

GUANGZHOU, China, Oct. 19, 2026 /PRNewswire/ -- On October 14, 2026, KAILAS hosted BEYOND THE GATE | KAILAS SNOW SEASON OPENING NIGHT in Guangzhou, marking the opening of the 2026/27 ski season. At the event, KAILAS founder Zhong Sir announced that the brand will become the title sponsor of the Freeride World Tour (FWT) China Series for the 2026/27 season, upgrading its partnership with the series from the previous season.

Unlike resort skiing on groomed slopes, freeride skiing takes place on natural, ungroomed terrain, where athletes assess snow conditions, select their lines and navigate the mountain according to their skills and risk awareness. The FWT China Series is scheduled to feature four FWT Qualifier events at Jikepulin Ski Resort in Hemu, Altay, Xinjiang, during two competition windows: December 9–15, 2026, and February 26–March 3, 2027. The series aims to connect Chinese riders with the international freeride competition pathway.

Beyond competition, KAILAS is building a broader skiing community through BEYOND THE GATE, connecting skiers with mountain culture, professional guidance and shared experiences. The initiative brings together coaches, guides and mountain skiers through ski lessons, backcountry safety education, experience sharing and destination services, encouraging more people to explore the mountains with knowledge, preparation and respect for the terrain.

KAILAS continues to support equipment development and real-world testing. Last season, the brand brought its BM45 freeride collection to Hemu for on-snow testing. At the event, KAILAS also showcased its TAIGA ski apparel, designed for extreme cold. The collection combines weather protection and thermal insulation with zoned breathability, a helmet-compatible hood, a powder skirt and RECCO® technology, which helps make wearers searchable by organized rescue teams in the event of an avalanche or when lost outdoors.

To help skiers navigate mountain environments with greater confidence, KAILAS plans to work with professional coaches and specialists in avalanche safety to provide ski lessons, backcountry safety education and experience-sharing opportunities. The brand is also expanding its destination services in locations such as Songhua Lake and Hemu, connecting skiers with local guides, equipment advice, courses, safety sessions and community activities.

Through competition partnerships, technical equipment and on-the-ground services, KAILAS seeks to support the growth of freeride skiing in China and help more skiers explore the mountains with knowledge, preparation and respect for the terrain.

Share this article

Innovative tunnel design supports O'Hare modernization while maintaining active airfield

operations

CHICAGO, Oct. 19, 2026 /PRNewswire/ -- The HNTB-designed South Conveyance Storm Sewer Project at O'Hare International Airport has received the American Society of Civil Engineers Illinois Section's 2026 Outstanding Civil Engineering Achievement Award in the more than $100 million category. The award recognizes the project's innovative tunnel solution constructed beneath active runways and taxiways while maintaining uninterrupted airport operations.

Delivered for the Chicago Department of Aviation, the project provides critical stormwater infrastructure to support O'Hare's continued modernization and future development. HNTB served as engineer of record for the project, working closely with the department and project partners to develop and implement the tunnel solution beneath active airfield infrastructure.

"The South Conveyance Storm Sewer Project is a critical investment in O'Hare's future," said CDA Managing Deputy Commissioner Zach Baughman, the ORDNext program chief. "Completed without interrupting airport operations, it strengthens our ability to provide the safe, reliable experience passengers and airlines depend on while advancing our long-term vision for O'Hare."

The tunnel was constructed through challenging subsurface conditions using a 17-foot-diameter earth pressure balance tunnel boring machine. During excavation, the machine advanced beneath two active runways and several taxiways while airport operations continued above. Real-time instrumentation and monitoring helped protect critical airfield infrastructure throughout excavation.

"Constructing a tunnel of this scale beneath an active airfield required careful planning, close coordination and precise control throughout excavation," said Mark Stephani, HNTB principal engineer of geotechnical and tunneling. "The team developed an innovative solution that managed complex ground conditions, reduced risk at critical runway crossings and delivered the stormwater capacity needed to support O'Hare's future."

The project was delivered using the construction manager at risk method, allowing early contractor involvement and collaboration. The approach helped the team evaluate construction alternatives, improve constructability and successfully advance the tunnel boring machine solution.

The project team received the award during the ASCE Illinois Section's Annual Awards Banquet in Chicago.

About HNTB

For more than a century, HNTB Corporation has been at the forefront of designing and advancing transportation infrastructure that enhances mobility and improves local communities. With client relationships spanning decades, we understand infrastructure life cycles and have perspective and experience to solve the most complex technical, financial and operational challenges with vision and imagination. As employee owners committed to excellence, we prioritize client success while delivering a full spectrum of infrastructure-related services. Discover HNTB's Spark at www.hntb.com, or follow us on LinkedIn, X, Facebook or Instagram.

SOURCE HNTB

Share this article

Complete Comfort Heating, Air and Plumbing provides steps to prepare for winter

The Indianapolis-area home service company recommends homeowners act now to ensure pipes are ready for cold temperatures

INDIANAPOLIS, Oct. 19, 2026 /PRNewswire/ -- Complete Comfort Heating, Air and Plumbing, a family-owned HVAC and plumbing service provider serving the Indianapolis area, recommends that homeowners take steps to ensure that pipes are winter-ready before frigid temperatures arrive.

According to State Farm's latest statistics on winter insurance claims for frozen pipe and water damage, the average payout was more than $30,000 when including flooring, drywall and personal property claims.

"A pre-winter plumbing inspection can help prevent frozen pipes when temperatures drop," said Kenneth Hale, owner of Complete Comfort Heating, Air and Plumbing. "Finding small cracks or corrosion early before the stress of cold temperatures gives homeowners the opportunity to schedule repairs and avoid an unexpected winter emergency."

In addition to a professional inspection, Hale recommends some proactive measures that homeowners can take to prepare for freezing weather:

- Insulate pipes in unheated spaces and along outside walls in kitchens and bathrooms.

- Drain outside garden hoses and pipes and cover or insulate faucets.

- Caulk and seal gaps in areas prone to drafts.

Hale adds that when temperatures reach freezing, opening cabinet doors to promote warm air circulation and streaming a small stream from faucets can help prevent ice from forming inside pipes.

"In addition to expensive insurance claims, repairing structural damage to walls, flooring and foundations often takes weeks or months," said Hale. "Investing in a routine plumbing inspection ahead of time helps ensure your home remains safe, comfortable and problem-free throughout the winter holidays."

For information about Complete Comfort Heating, Air and Plumbing, visit https://completecomfortgo.com/.

About Complete Comfort Heating, Air and Plumbing

Complete Comfort Heating, Air and Plumbing is a trusted provider of HVAC and plumbing services in the greater Indianapolis area. Owned by local businessman Kenneth Hale, the company is known for its commitment to quality workmanship and customer satisfaction. It offers comprehensive heating, cooling and plumbing solutions for residential and commercial customers. With a focus on integrity, reliability and community involvement, Complete Comfort strives to deliver comfort and peace of mind to every customer it serves. For more information, visit completecomfortgo.com/.

SOURCE Complete Comfort Heating, Air and Plumbing

Share this article

15 products, including pre-workout, creatine, and protein, now in the sporting goods aisle at 1,800+ Target stores.

OREM, Utah, Oct. 19, 2026 /PRNewswire/ -- Pre-workout. Creatine. Protein. One Target run. Bucked Up®, the #1 pre-workout in the U.S.**, and one of the fastest-growing health and wellness brands in the U.S., is launching at Target for the first time with 15 products in approximately 1,848 stores nationwide and on Target.com. Find it in the sporting goods section, right next to the gear.

Ten Years In. Now at Target.

Bucked Up® started in 2016 with a transparency-first label that showed every ingredient and every dose. Ten years later, it's a $450 million brand in 100,000+ retail locations, and Target is the next stop. Same formulas. Same fully disclosed labels. Now part of the weekly Target run.

"For ten years, we've built Bucked Up® on one promise: no shortcuts, no secrets, no compromises. Target gives us the chance to bring that standard to millions right where they shop for the rest of their fitness routine," said Erin Bettner, Chief Marketing Officer of Bucked Up®.

15 Products. Three Ways to Get Bucked Up.

Pre-Workout: Energy that gets you in the door.

- Bucked Up® Pre-Workout: Blood Raz (Raspberry), Blue Raz (Blue Raspberry), 25 servings

- Big Bucks™: Maxed Out Mango, Rocket Pop, 20 servings

- Babe™ Pre-Workout: Lavender Lemonade, made for women by women, 25 servings

Creatine: Strength, built daily, however you take it.

- Bucked Up® Essentials™ Creatine Monohydrate: Unflavored (NSF Certified for Sport®), Fruit Punch, 50 servings

- Bucked Up® Creatine Candy™: Variety Pack (Blue Raz, Green Apple, Watermelon, Tropical Blast), 24 servings

- Bucked Up® Creatine Gummy Bucks: Variety Pack, 25 servings

Ready-to-drink Lightly Carbonated Protein: Clear, crisp protein that fuels recovery.

- Bucked Up® Lightly Carbonated Protein, 16oz: Orange Cream, Rainbow Candy, Peach Mango, Banana Pineapple, Cherry Limeade, Green Apple

Scoop It, Chew It, or Crack It Open.

Creatine builds lean muscle, improves recovery, and supports brain function.* Bucked Up® makes it in whatever format fits the routine.

Scoop it. Full label transparency has been the Bucked Up® standard since 2016. NSF Certified for Sport® holds it to that standard from the outside. Bucked Up® Essentials™ Creatine Monohydrate (Unflavored) is independently tested by NSF to confirm that what's on the label is exactly what's in the tub, screened for substances banned in sport, and made in an NSF-audited facility, the same standard trusted by professional and collegiate athletes. Inside: one ingredient, 5g of micronized creatine monohydrate. Zero fillers. Zero extras. Creatine helps muscles regenerate ATP, the energy your cells burn through during heavy lifts and sprints.* Take it daily and you may feel more explosive on heavy sets, push out more reps at a given weight, and recover faster between sessions.* Micronized means it mixes smoother and dissolves more completely, with no grit and no residue. And 5g is the standard daily maintenance dose, so there's no guesswork and no underdosing.*

Chew it. No shaker. No water. No mixing. Creatine Candy™ packs the same 5,000mg of micronized creatine monohydrate into five chewable tablets a day, in Blue Raz, Green Apple, Watermelon, and Tropical Blast. Toss it in a gym bag, desk drawer, or car console, so the daily habit never gets skipped. It's third-party tested, non-GMO, and gluten-free, with 24 servings per tub. Rather have a gummy? Creatine Gummy Bucks delivers the same 5,000mg of creatine per serving in a 25-serving variety pack.

Crack it open. The Bucked Up® Lightly Carbonated Protein drink goes the other way from a thick, creamy shake. It's clear, lightly carbonated, and refreshing, with 25g of protein per can in six flavors built for after the workout.*

Find It at Target.

Bucked Up® is available now at Target stores nationwide and on Target.com. Assortment varies by store. See the full Bucked Up® lineup at www.buckedup.com.

About Bucked Up®

Founded in 2016 in Salt Lake City, Utah, Bucked Up® is one of the nation's fastest-growing health and wellness brands. Backed by science and a bold motivational mission, the lineup spans pre-workout, energy drinks, protein, creatine, and more. Available at www.buckedup.com and 100,000+ retail locations, including Target, GNC, Vitamin Shoppe, and Walmart, united by one belief: everyone deserves to Feel Like a Million Bucks™.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

**According to yearly SPINS data ending September 2026.

SOURCE Bucked Up

Share this article